amino.flo Facebook ad: “The FDA’s own scientists just recommended AGAINST 7…”

About this ad

Meta Ad Library ID

1374271024641757

Platforms

Instagram

Relaunches

0

How we count

Ad text

The FDA’s own scientists just recommended AGAINST 7 of the most-used research peptides. The advisory committee still votes July 23–24. 🧬 Here’s what’s actually happening — and why it matters even if you only follow peptides from the sidelines. On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets to decide whether 7 peptides can stay legally available through compounding pharmacies: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon. The twist? The FDA’s own reviewers already published documents proposing NOT to add them. Yet the panel that votes was just reshuffled. Swipe for the full breakdown 👉 Want the live tracker as results drop? Comment “FLO” for our free research Discord. Not medical advice. Educational & research purposes only. 📖 What’s the “503A Bulks List”? 503A is the section of federal law covering traditional pharmacy compounding — customized medications prepared for an individual patient. For a substance to be legally compounded under 503A (when no FDA-approved version exists), it generally needs to be on the FDA’s 503A Bulks List. Making that list is the difference between a peptide being compoundable in the US — or not. That’s exactly what’s on the table July 23–24, 2026: seven peptides reviewed for that list — BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax, Epitalon. This is the moment that shapes legal access for the whole category. Not medical advice. Educational purposes only. 📖 How did we get here? Meet “Category 2.” In late 2023, the FDA sorted roughly 19 popular peptides into Category 2 — its bucket for bulk substances that may “raise significant safety risks” pending review. In practice, Category 2 pumped the brakes on compounding them. Then in April 2026, the FDA removed about a dozen peptides from that list and teed them up for formal advisory review. So the July meeting isn’t a surprise crackdown — it’s the next scheduled step in a process that’s been unfolding for over two years. (Sources: FDA compounding bulk-substance categories; FDA advisory committee meeting notices.) Not medical advice. Educational purposes only. 📖 The plot twist, explained. Before a PCAC meeting, the FDA po

Where the ad sends people